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Thiazolidinediones (TZDs) are synthetic PPARγ (peroxisome proliferator-activated receptor gamma) agonists and a class of drugs
for diabetes mellitus type 2 that can decrease blood sugar eﬃciently by enhancing insulin sensitivity. However, increased bone
fracture risk in diabetic individuals treated with TZDs is one of the reported side eﬀects. Recent studies show that TZDs such as
rosiglitazone simultaneously inhibit osteoblast diﬀerentiation and activate osteoclast diﬀerentiation, leading to bone loss due to
decreased bone formation and increased bone resorption. Furthermore, TZDs may activate PPARγ in tissues other than bone,
such as the hypothalamus-pituitary-gonad (HPG) axis to indirectly regulate bone mass. This paper will focus on current new
developments that implicate potential mechanisms for how PPARγ modulates skeletal homeostasis and how TZDs exert bone-loss
side eﬀects.
1.Introduction
Rather than a rigid and dormant organ that merely serves an
inert support for the vertebrates, bone is a highly dynamic
tissue that undergoes constant remodeling, adaptation,
repair, and regeneration. Evolution has crafted the structure
of the skeletal system in such an elegant way that it is light
weighted so birds can ﬂy, yet strong so cheetah can run and
hunt. The quantity and quality of bone are inﬂuenced by
both genetic traits and environmental factors such as nutri-
tion,exercise,andhormone.Bonelossorosteoporosisoccurs
in physiological and pathological conditions such as aging,
postmenopause, sedentary lifestyle, weightlessness during
spaceﬂight, diabetes, and bone metastasis of cancers. With
the extension of lifespan and changes in life style, osteoporo-
sis and bone fractures are becoming a leading cause of mor-
bidity and mortality in the modern society. It is estimated
that an osteoporotic fracture occurs every 3 seconds world-
wide [1]; one out of three women and one out of ﬁve men
over50yearsofagewillexperienceosteoporoticfractures[2–
4]. Between 1990 and 2000, there was nearly a 25% increase
in hip fractures worldwide [1]; by 2050, the worldwide inci-
dence of hip fracture is projected to increase by 310% in men
and 240% in women [5]. Osteoporosis takes a huge personal
and economic toll, for example, in women over 45 years of
age, it accounts for more days spent in hospital than many
other diseases including diabetes, myocardial infarction, or
breast cancer [6]. However, the great majority (>80%) of
high-risk individuals are neither identiﬁed nor treated [7].
Therefore, enhanced understanding of bone biology and
development of eﬀective diagnosis, prevention, and treat-
ment for osteoporosis are of paramount medical urgency
and clinical signiﬁcance.
Bone harnesses an enormous ability to repair and re-
generate—both quantity and quality of the bone are main-
tained by an intricate cellular network composed mainly
of three cell types: osteoclasts, osteoblasts, and osteocytes.
Osteoclasts are bone-resorbing cells responsible for remov-
ing old bones, which are diﬀerentiated from hematopoietic
progenitors of the monocyte/macrophage lineages upon
activation by cytokines such as RANKL (receptor activa-
tor of nuclear factor kappa-B ligand) [8–12]. Osteoblasts
are bone-forming cells responsible for generating and min-
eralizing new bone, which are diﬀerentiated from mesenchy-
mal progenitors upon activation of several transcription
factors such as runx2 and osterix [13–15]. Osteocytes are
the most abundant cells in the bone matrix that are thought
to derive from osteoblasts, and regulate numerous func-
tions including mechanical sensing, bone remodeling, and
mineral metabolism, by both physical interaction and2 PPAR Research
paracrine/endocrine signaling [16, 17]. The balance between
bone resorption by osteoclasts and bone formation by os-
teoblasts is critical for skeletal homeostasis, and bone loss
occurs when resorption outpaces formation.
2. TZDs CauseBone Loss andHigher Fracture
RatesinDiabeticPatients
Thiazolidinediones (TZDs—troglitazone, rosiglitazone, pio-
glitazone, and netoglitazone) are widely used for the man-
agement of diabetes mellitus type 2. On the one hand, TZDs
can enhance glucose uptake, by increasing insulin-sensitivity
of adipocytes, muscle, liver, macrophages, and so forth; on
the other hand, TZDs can also inhibit gluconeogenesis in the
liver, both resulting in decreased insulin resistance and lower
blood sugar levels [18, 19]. However, as a common sense,
drugs are often accompanied with side eﬀects and TZDs is
not an exception. In addition to side eﬀects such as weight
gainandﬂuidretention,increasingreportsindicatethatboth
rosiglitazone and pioglitazone are associated with a higher
fracture risk. With 4 years of rosiglitazone treatment, type 2
diabetic patients in ADOPT (A Diabetes Outcome Progres-
sionTrial)showedincreasedincidenceoffracturesinwomen
[20]. Similarly, pioglitazone is also reported to have the same
side eﬀect [21]. Moreover, by taking paired stored baseline
and 12-month serum samples from 1605 participants (689
women, 916 men) in ADOPT, a recent study showed that
CTX-1(C-terminaltelopeptidefortype1collagen),amarker
for osteoclast activity and bone resorption, was increased
by 6.1% in the rosiglitazone-treated group in women but
not men; P1NP (procollagen type 1 N-propeptide) and bone
alkaline phosphatase, two markers for osteoblast activity and
bone formation, were decreased in both women and men
treated with rosiglitazone [22]. This indicates that elevated
bone resorption and suppressed bone formation are two
important mechanisms that contribute to the bone loss side
eﬀects and the higher fracture risk in women taking TZDs
[22].
Importantly, emerging evidence indicates that metabolic
state may inﬂuence the eﬀects of TZDs on bone [23].
For example, epidemiological studies suggest that skeletal
fragility is already increased in type 2 diabetes mellitus [24,
25],potentiallyduetotheinhibitionofosteoblastdiﬀerentia-
tionandfunctionbyhyperglycemia-associatedROS(reactive
oxygen species) accumulation and/or glucose toxicity [26–
28]. Thus, rosiglitazone-induced bone loss may be exacer-
batedindiabeticpatientscomparedwithhealthyindividuals.
An important question for future study is whether and
how diﬀerent metabolic states such as obesity, diabetes,
insulin resistance, and aging modulate the relative eﬀects of
TZDs on bone resorption versus formation. The purpose
of this review is to survey in vivo and in vitro evidence
supporting direct and indirect eﬀects of TZDs on osteoclasts
and osteoblasts, thus proposing hypotheses for future inves-
tigations (Figure 1).
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Figure 1:PotentialmechanismsforTZD-inducedboneloss.Invivo
studies in both clinical trials and using animal models demonstrate
that TZDs, a class of diabetic drugs that functions as PPARγ
agonists, cause bone loss and increased fracture risk, especially
in postmenopausal women, by simultaneously inhibiting bone
formation and stimulating bone resorption. In addition to the well-
documented direct eﬀects of TZDs on bone cell diﬀerentiation
and function, emerging evidence indicate that TZD may also
exert its detrimental skeletal eﬀects via several potential indirect
eﬀects, which provokes further investigation in future preclinical
and clinical studies.
3. PPARγ Regulates Osteoblastogenesis and
Osteoclastogenesis
PPARγ (peroxisome proliferator-activated receptor gamma)
is a member of the nuclear receptor superfamily of transcrip-
tion factors that can be activated by lipophilic ligands [29].
Upon ligand activation, PPARγ typically induces target gene
expression by binding to PPAR response elements (PPREs)
in the promoter regions as a heterodimer with the retinoid
X receptor (RXR) and recruiting transcription coactivators
[29].AccumulatingevidencedemonstratesthatPPARγ func-
tions as a key regulator of skeletal homeostasis by directly
regulating the diﬀerentiation of bone cells.
It has been ﬁrst reported that PPARγ exerts negative
eﬀects on osteoblast diﬀerentiation and bone formation.
Homozygous PPARγ-deﬁcient embryonic stem cells failed to
diﬀerentiate into adipocytes, but spontaneously diﬀerenti-
ated into osteoblasts; heterozygous PPARγ-deﬁcient mice
exhibited high bone mass, resulting from enhanced osteo-
blastogenesisfrombonemarrowmesenchymalstemcellsbut
reduced adipogenesis [30]. Consistently, PPARγ activation
byTZDtreatmentinhibits osteoblastdiﬀerentiation butpro-
motes adipocyte diﬀerentiation [31–33]. Moreover, recent
evidence has revealed that TZDs may also negatively impact
bone by inducing osteocyte apoptosis and the expressionPPAR Research 3
of sclerostin, a Wnt antagonist and an inhibitor of bone
formation [34, 35].
Subsequently, PPARγ has been found to also enhance
RANKL-mediated osteoclast diﬀerentiation from hemato-
poietic stem cells [36]. PPARγ deletion in mouse hemato-
poieticlineagescausedosteoclastdeﬁciency,leadingtoosteo-
petrosis manifested as high bone mass and extramedullary
hematopoiesis in the spleen, as well as resistance to ros-
iglitazone-stimulated bone resorption [36]. At molecular
levels, PPARγ activation by rosiglitazone suppresses β-
catenin protein levels and function [37, 38], induces the
expression of PGC1β (peroxisome proliferator-activated re-
ceptor gamma coactivator 1-beta), and potentiates RANKL-
induced transcription of c-fos, an essential mediator of
osteoclastogenesis [36, 37]. Interestingly, growing evidence
suggest that osteoclastogenesis can occur via noncanonical
pathways in which RANKL can be substituted by other
g r o w t hf a c t o r ss u c ha sT N F α, LIGHT (TNFSF14), IL-6,
TGFβ, APRIL, BAFF, NGF, IGF-I, or IGF-II [39–46]. In
future studies, it would be important to determine the eﬀects
of TZD treatment on the osteoclastogenesis mediated by
these RANKL-independent pathways.
Pharmacologically, recent clinical trials report that long-
term use of TZDs, such as rosiglitazone, increases fracture
rates among diabetic patients [20, 22, 24, 47, 48]. Using
animalmodelssuchasmiceandrats,numerousstudiesshow
that TZDs cause bone loss by simultaneously decreasing
bone formation and increasing bone resorption, thus the
uncoupling of bone remodeling [23, 31, 36, 37, 49, 50].
Together, these ﬁndings indicate that TZD-induced skeletal
fragility is mainly achieved by bone cell-autonomous PPARγ
activation, which inhibits osteoblastogenesis and enhances
osteoclastogenesis.
4. OPG/RANKL inOsteoclastogenesis
The cytokines RANKL (receptor activator of nuclear factor
NF-κB ligand) and MCSF (macrophage colony stimulating
factor) are required for the diﬀerentiation from osteo-
clasts progenitors into mature osteoclasts. MCSF func-
tions through its receptor MCSFR (c-fms) to promote
macrophage/osteoclast precursor proliferation and survival.
Upon binding to its receptor RANK, RANKL activates
several key transcription factors such as c-fos, c-jun, NFATc1
(nuclear factor of activated T cells, cytoplasmic 1), and NF-
κB, as well as osteoclastic enzymes such as TRAP (tartrate-
resistant acid phosphatase) and CTSK (cathepsin K), which
concertedlytriggerthediﬀerentiation,multinucleation,mat-
uration, and activation of osteoclasts [12, 51]. As a counter
balance, osteoprotegerin (OPG) is a naturally occurring
decoy receptor for RANKL, thereby inhibiting osteoclastoge-
nesisandboneresorption[51].SelectivelyblockingOPGwill
increase RANKL activity and osteoclastogenesis, leading to
osteoporosis eventually. Both RANKL and OPG are secreted
from osteoblasts to regulate osteoclast diﬀerentiation; there-
fore, RANKL/OPG ratio is a critical factor that regulates the
balance between osteoblasts and osteoclasts, thus the cou-
pling between bone formation and resorption.
In addition to PPARγ expressed endogenously in the
osteoclasts, PPARγ in other cell types have also been shown
to indirectly inﬂuence osteoclastogenesis. It has been impli-
cated that PPARγ activation in osteoblast or adipocytes may
promote osteoclast diﬀerentiation by inducing the expres-
sion of RANKL [23, 52]. Another recent study reported
that osteoblast-speciﬁc overexpression of PPARγ led to lower
bone mass in male mice and accelerated ovariectomy-
induced bone loss in female mice, associated with not only
decreased bone formation but also increased RANKL/OPG
ratio [53]. These studies further support the notion that
TZDs-induced skeletal fragility is mediated by multifaceted
actions of PPARγ on both osteoblast and osteoclast, via both
cell-autonomous and paracrine regulations.
Interestingly, recent studies have reported that TZDs can
also aﬀect systemic OPG levels. After 24 weeks of treatment
of pioglitazone or metformin in 67 type 2 diabetic patients,
it was found that plasma levels of OPG decreased in the
pioglitazone group, but were unchanged in the metformin
group[54]. A similar study showed that comparing 46 type 2
diabetic patients treated with TZDs with 152 type 2 dia-
betic patients receiving other oral antidiabetes drugs, TZDs
treatment is associated with a decrease in plasma OPG
levels [55]. Besides in vivo, PPARγ agonists have also been
shown to downregulate OPG levels in vitro. Troglitazone can
decrease OPG concentration in a dose-dependent manner in
8-day-cultured human mesenchymal stem cells (hMSCs); on
the contrary, PPARγ inhibitor GW9662 can enhance early
OPG protein levels by hMSCs [56]. Together, these studies
have identiﬁed RANKL and OPG as potential contributing
factors for the enhanced osteoclastogenesis and bone resorp-
tion associated with TZDs, suggesting that pharmacological
reduction of the RANKL/OPG ratio may be novel strategies
to combat TZD-induced bone loss.
5. Sex Hormone Receptors and
Osteoclast Survival
Estrogen is osteoprotective, and estrogen decline plays an
important role in postmenopausal osteoporosis. First, estro-
gen is implied to decrease the osteoclastic resorption pit in
bone by regulating several transcription factors (c-fos, c-jun,
e.g.)andinﬂammatorycytokines(IL-1RI,IL-1RII,e.g.)[57].
Second, our recent study reveals that estrogen loss in mice by
ovariectomy stimulates osteoclast progenitors to proliferate
and diﬀerentiate; suggesting estrogen also inhibits osteoclas-
togenesis in vivo [58]. Third, estrogen has been shown to
promote osteoclast apoptosis [59, 60]. This suggests that
estrogen antagonizes osteoclast diﬀerentiation and function,
and potentially suppresses PPARγ-stimulated osteoclastoge-
nesis. Consistently, estrogen has been shown to be protective
against TZD-induced bone loss, for example, TZD-induced
bone loss is more signiﬁcant in postmenopausal women
[22, 61, 62]; estrogen signiﬁcantly reduces TZD-induced
adipogenesis [63], osteocyte apoptosis, and sclerostin upreg-
ulation [34]. Interestingly, a recent study shows that TZDs
(rosiglitazone or pioglitazone) also inhibit estrogen synthesis4 PPAR Research
in human granulosa cells by interfering with androgen bind-
ing to aromatase, thus directly aﬀecting estrogen production
in human ovarian cells [64]. Together, these ﬁndings suggest
another potential contributing mechanism for TZD-induced
osteoclast activation and bone loss, which may involve the
suppression of estrogen function and/or production. In
future investigations, it would be important to further ex-
amine the in vivo eﬀects of TZDs on estrogen synthesis and
activity in animal models and in clinical trials.
Among the two estrogen receptor isoforms (ERα and
ERβ), ERα is mainly responsible for estrogen regulation of
osteoclast survival [60]. ERα diminishes mature osteoclast
lifespan through the induction of the proapoptotic Fas
ligand (FasL) [60]. Selective deletion of ERα in diﬀerentiated
osteoclasts in the ERαΔOc/ΔOc female mice led to a lower
bone mass, mimicking the postmenopausal osteoporosis in
women [60]. In contrast, in the functional FasL knockout
mice (FasLgld/gld), neither enhanced bone resorption nor
bone loss was induced by osteoclastic ERα deﬁciency [60].
Thus, in diﬀerentiated osteoclast, FasL expression appears
to be positively controlled by activated ERα. In addition to
the role for FasL in estrogen-induced osteoclast apoptosis
by an autocrine mechanism involving osteoclasts alone [60],
another study has proposed a paracrine mechanism in which
estrogen aﬀects osteoclast survival through the upregulation
of FasL in osteoblasts (and not osteoclasts) leading to the
apoptosis of preosteoclasts [59].
A recent study has shown that in two hormone-de-
pendent breast cancer cell lines (MCF-7 and ZR-75-1),
PPARγ activationcouldleadtoERαdownregulationthrough
the proteasome-dependent degradation pathway [65]; yet
diﬀerent PPARγ agonists exerted diﬀerential eﬀects on
ERα stability: troglitazone, ciglitazone, and natural PPARγ
ligand 15d-PGJ(2) induced ERα degradation eﬃciently
while rosiglitazone did not alter ERα protein levels [65].
Interestingly, another recent study has shown that in MCF7
cells, rosiglitazone could increase the transactivation of FasL
promoter through Sp1 site in a dose-related and PPARγ-
dependent manner, which could be abrogated by PPARγ
antagonist GW9662 [66]. It concludes that PPARγ triggers
apoptotic events in breast cancer cells via Fas/FasL signaling
pathway [66]. In osteoclasts, the eﬀects of PPARγ activation
on ERα degradation and FasL expression are underexplored,
thus begging the question whether TZDs promote osteoclast
survival by reducing ERα protein, or promote osteoclast
apoptosis by inducing FasL mRNA. Therefore, to determine
how PPARγ regulates osteoclast activity, it would be impor-
tant to investigate both cell-autonomous eﬀects of TZDs on
ERα/FasLpathwayandosteoclastsurvival;aswellassystemic
eﬀects of TZDs on estrogen production and its induction of
osteoclast apoptosis.
In addition to ERα, there are other transcription factors
that potentially regulate the functions of estrogen. For exam-
ple, the orphan nuclear receptor estrogen-related receptor
α (ERRα) has been shown to regulate many of the same
genes as ERα [67, 68], and modulate the activity of ERα in
varioustissuesincluding breast,uterus,andbone[69].ERRα
has been shown to be involved in the control of not only
energy metabolism but also skeletal homeostasis. The roles
of ERRα in osteoblastogenesis are being actively investigated,
and conﬂicting results have been reported that ERRα can
either activate or inhibit osteoblast diﬀerentiation [70].
Furthermore,ourrecentstudyrevealsanothernovelfunction
for ERRα in enhancing osteoclastogenesis by inducing the
expression of mitochondrial genes via a PGC1β-dependent
pathway [37]. Induced by PPARγ and coactivated by PGC1β,
ERRα not only promotes mitochondrial activation but also
increase osteoclast diﬀerentiation [12, 37]. On the one hand,
reactive oxygen species (ROS), released from mitochondria,
can stimulate osteoclast diﬀerentiation by promoting Ca2+
oscillations and NFATc1 activation; on the other hand, sev-
eral transcription factors induced during osteoclastogenesis
can activate the expression of target genes required for
mitochondrial biogenesis [12, 37, 71]. Consequently, ERRα
knockout mice exhibit decreased osteoclasts number, bone
resorption,andhigherbonemass[37].Becauseofthecrucial
role of estrogen deﬁciency in postmenopausal osteoporosis,
it will be interesting in future studies to determine whether
and how the PPARγ/PGC1β/ERRα pathway interacts with
the ER signaling in bone remodeling.
6.Hypothalamic-Pituitary-Gonadal(HPG)Axis
andBone Remodeling
Although TZDs have been shown to modulate skeletal
homeostasis by directly activating PPARγ in bone cells and
regulatingosteoblast/osteoclastdiﬀerentiation,newevidence
implies that TZDs may also function indirectly through
PPARγ in other tissues such as the hypothalamus. A recent
study has unveiled an unknown role for central nervous sys-
tem (CNS) PPARγ in the regulation of energy balance [72]:
both acute and chronic activation of CNS PPARγ, by either
TZDs or hypothalamic overexpression of a fusion protein
consisting of PPARγ and the viral transcriptional activator
VP16 (VP16-PPARγ), led to positive energy balance in rats,
includingcumulativefoodintakeandbodyfatgain.Blocking
the endogenous activation of CNS PPARγ with pharmaco-
logical antagonists or reducing its expression with shRNA
led to negative energy balance, restored leptin sensitivity in
high-fat-diet-fed rats and blocked the hyperphagic response
to oral TZD treatment [72]. These ﬁndings implicate a
provocativehypothesistobetestedinfuturestudiesthatCNS
PPARγ may also contribute to the regulation of bone mass
by TZDs, potentially via the hypothalamic-pituitary-gonadal
(HPG) relay.
The classic theory predicts that sex steroid (estrogen
and androgen) deﬁciency is the main cause of osteoporo-
sis; however, emerging evidence indicate that other hor-
mones in the hypothalamic-pituitary-gonadal (HPG) axis
also participate in the maintenance of bone homeostasis
[73]. Progesterone, normally modulated by estrogens, is a
female hormone important for the regulation of ovulation,
pregnancy, and menstruation. It has been shown that pro-
gesterone increases osteoblasts numbers and promotes
osteoblastsdiﬀerentiationandmaturation,whichisindepen-
dence of estrogen [74]. Another recent study has reported
that the osteoclast diﬀerentiation factor RANKL functions asPPAR Research 5
an important in vivo molecular link between progesterone
and epithelial carcinogenesis by controlling the incidence
and onset of progesterone-driven mammary cancer [75].
This suggests that progesterone may also regulate RANKL-
induced osteoclastogenesis. Concerning PPARγ, its agonist,
rosiglitazone, can generally antagonize progesterone activity
bystimulatingprogesteronereceptor(PR)Bdegradationand
blocking progesterone-induced PRB phosphorylation [76].
Together, these ﬁndings suggest that PPARγ regulation of
bone homeostasis may be also partially mediated by mod-
ulating progesterone function, which remains to be further
investigated in future studies.
Activin and inhibin, two closely related protein com-
plexes secreted from the gonad, are members of the trans-
forming growth factor beta (TGFβ) family, which controls
cell proliferation and diﬀerentiation in many organs. Activin
is either a homodimer composed of two identical βA( a c t i vi n
A) or βB (activin B) subunits or a heterodimer of βAa n d
βB (activin AB); inhibin is a heterodimer comprised of αβA
(inhibin A) and αβB (inhibin B) subunits, and α subunit is
unique to inhibin. Activin and inhibin exert opposite bio-
logical eﬀects in a variety of cell types. For examples, activin
enhances whereas inhibin suppresses follicle-stimulating
hormone (FSH) biosynthesis and secretion from the anterior
pituitary [77]. Cellular and physiological evidence show
that both activins and inhibins regulate osteoblastogenesis
and osteoclastogenesis, thus modulating bone mass in vivo
[78]. Interestingly, PPARγ has been reported to crosstalk
with activin A: on the one hand, activin A treatment can
inhibit PPARγ expression in 3T3-L1 preadipocytes, leading
toreducedadipocytesdiﬀerentiation[79];ontheotherhand,
PPARγ activation by rosiglitazone can decrease follistatin
(activinAantagonist)mRNAlevelsinratintestinalepithelial
cells, leading to the gain-of-function of activin A, which
mediates the eﬀects of TZDs on cell proliferation [80].
These results suggest that PPARγ may also interact with the
activin/inhibin pathways to regulate bone remodeling, which
represents another important future direction for investiga-
tion.
Follicle-stimulating hormone (FSH), derived from pitu-
itary, has been proposed to regulate bone mass via sev-
eral controversial and contradictory mechanisms. In peri-
menopausal women, increase of serum FSH, but not loss
of estrogen, has been reported to better correlate with bone
turnover and/or BMD across the menopause transition [81–
83]. It has been shown that FSH enhances osteoclastogenesis
by activating MEK/Erk, NF-κB, and Akt; furthermore, FSHβ
KO mice and FSH receptor (FSHR) KO mice are resistant
to bone loss despite severe hypogonadism; FSHβ+/− mice
exhibit increased bone mass and decreased osteoclastic
resorption with normal ovarian function, suggesting that the
skeletal action of FSH is estrogen independent [84]. In
contrast,tworecentreportshaveprovidedoppositeevidence.
First, in a prospective clinical study, it has been found that
suppression of FSH secretion by a GnRH agonist failed to
reduce bone resorption markers in postmenopausal women
[85]. Second, using FSH transgenic mice, it has been
shown that FSH has dose-dependent anabolic (rather than
catabolic) eﬀects on bone, via an ovary-dependent and
nonbone-cell-autonomousmechanism[86].PPARγ ishighly
expressed in the pituitary [87]. It has been reported that
PPARγ and TZDs can alter the secretion and function of
pituitaryhormones.Forexamples,pituitary-speciﬁcdeletion
of PPARγ increases luteinizing hormone (LH) levels in
female mice and decreases FSH levels in male mice [88];
TZD activation of PPARγ inhibits LH secretion [89]a n d
gonadotropin-releasing hormone (GnRH) signaling [88].
Together, these reports warrant future investigations on the
hypothesis that TZDs may partially exert its eﬀects on bone
by regulating hormones in the HPG axis such as GnRH, LH,
and FSH.
Oxytocin is another pituitary hormone related to the
bone homeostasis. Oxytocin has been shown to regulate
the diﬀerentiation outcome of mesenchymal stem cells by
trending toward osteoblasts but inhibiting adipocytes [90].
As oxytocin receptor is expressed and functional in human
osteoclasts [91], the possibility exists that oxytocin modu-
lates bone mass by also regulating osteoclastogenesis. Clin-
ically, it is shown that plasma oxytocin levels are signiﬁcantly
lower in postmenopausal women developing osteoporosis
than in their healthy counterparts [90]. Mechanistically,
oxytocin increases bone morphogenetic protein 2 (BMP2)
expression, consequently upregulates the functions of
Schnurri-2and3,Osterix,andATF-4,allofwhichareknown
activators of osteoblastogenesis [92]. Interestingly, PPARγ
has been shown to also crosstalk with oxytocin signaling:
in contrast to the aforementioned report [90], oxytocin was
reportedtostimulateadipocytesdiﬀerentiationbyincreasing
expression of PPARγ, fatty acid binding protein (FABP),
insulin-sensitive glucose transporter 4 (GLUT4), leptin, and
CD31 in the epididymal and/or retroperitoneal fat tissue of
oxytocin-treated rats [93]. Similar to oxytocin, as another
pituitaryhormone,prolactinalsoregulatesboneremodeling.
In osteoblast-like cells, MG-63, prolactin inhibits osteoblas-
togenesis and promotes osteoclastogenesis by increasing the
ratio of RANKL/OPG [94]. Prolactin signaling has also been
shown to interact with PPARγ pathway. On the one hand,
prolactin enhances PPARγ and C/EBPβ mRNA production
and augments adipocytes diﬀerentiation in NIH-3T3 cells
[95]; on the other hand, TZDs activation of PPARγ inhibits
prolactin function in pituitary tumor cells [96]. These
observations suggest that the eﬀects of TZD and PPARγ
on bone remodeling may be also modulated by pituitary
hormones such as oxytocin and prolactin, which needs to be
further examined in both animal models and clinical investi-
gations in the future.
7. Concluding Remarks
In light of the vast array of potential target tissues, phar-
macological and mechanistic understanding of cell type-
speciﬁc gene regulation by PPARγ a n dT Z D sw i l lh e l pt o
design improved diabetic drugs, such as selective PPARγ
modulators, which retain high potency to treat diabetes with
minimal bone loss side eﬀects [12, 97]. By using ligands with
distinct chemical structures, it has been shown that diﬀerent
PPARγ functions could be separated. Unlike other TZDs,6 PPAR Research
netoglitazone(MCC-555,RWJ-241947)servesasanexample
of a selective PPARγ modulator that can distinguish the
antiosteoblastogenic and proadipogenic functions of PPARγ;
mice treated with netoglitazone showed decreased glucose
levels similarly to rosiglitazone, but without bone loss [98].
Moreover, a recent study reveals that the proadipogenic
eﬀects and insulin-sensitizing eﬀects of PPARγ can be
separated using partial agonists that selectively block cdk5-
induced PPARγ phosphorylation [99]. As an alternative
strategytoimprovetheoutcomeofTZDtreatmentbylessen-
ing the side eﬀects, combination therapies haven been used.
A recent report suggests that TZD/metformin combination
therapy is associated with less weight gain than TZD
monotherapy [100]. Thus, if used together with bone ana-
bolic and/or anticatabolic drugs, the TZD-mediated bone
loss side eﬀects may be dampened. More provocatively,
because PPARγ acts as a double-edged sword to not only
inhibit bone formation but also promote bone resorption,
bone-speciﬁc PPARγ antagonists may represent a potential
new therapeutic strategy for the simultaneous anabolic and
anticatabolic treatment of osteoporosis.
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